We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

419 hedge funds and large institutions have $9.23B invested in Neurocrine Biosciences in 2021 Q1 according to their latest regulatory filings, with 77 funds opening new positions, 161 increasing their positions, 127 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more call options, than puts

Call options by funds: $69.4M | Put options by funds: $52.1M

28% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 60

27% more repeat investments, than reductions

Existing positions increased: 161 | Existing positions reduced: 127

7% more capital invested

Capital invested by funds: $8.6B → $9.23B (+$636M)

5.45% more ownership

Funds ownership: 95.84% → 101.28% (+5.4%)

3% more funds holding

Funds holding: 405 → 419 (+14)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

Holders
419
Holders Change
+14
Holders Change %
+3.46%
% of All Funds
7.36%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
77
Increased
161
Reduced
127
Closed
60
Calls
$69.4M
Puts
$52.1M
Net Calls
+$17.2M
Net Calls Change
+$93.8M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$419M
2
PHS
PFM Health Sciences
California
+$111M
3
State Street
State Street
Massachusetts
+$82.8M
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$79.7M
5
DM
Deerfield Management
New York
+$76M

Top Sellers

Rank Fund Capital Flow
1
Capital International Investors
Capital International Investors
California
-$193M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$132M
3
PA
Perceptive Advisors
New York
-$100M
4
RSCM
Rock Springs Capital Management
Maryland
-$58.7M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$52.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Nomura Asset Management
151
Nomura Asset Management
Japan
$2.94M -$113K -1,082 -3%
CCP
152
Cardan Capital Partners
Colorado
$2.85M +$3.07M +29,289 New
US Bancorp
153
US Bancorp
Minnesota
$2.83M +$772K +7,366 +34%
AP
154
AtonRa Partners
Switzerland
$2.76M +$313K +2,986 +12%
OAM
155
Oppenheimer Asset Management
New York
$2.7M +$266K +2,532 +10%
DLPIC
156
Davide Leone & Partners Investment Company
United Kingdom
$2.54M +$806K +7,688 +42%
AIP
157
Ameritas Investment Partners
Nebraska
$2.51M +$2.71M +25,800 New
ASRS
158
Arizona State Retirement System
Arizona
$2.49M +$19.6K +187 +0.7%
CSS
159
Cubist Systematic Strategies
Connecticut
$2.49M +$1.2M +11,407 +80%
SM
160
SG3 Management
Puerto Rico
$2.43M +$2.62M +25,000 New
Thrivent Financial for Lutherans
161
Thrivent Financial for Lutherans
Minnesota
$2.43M +$2.62M +24,975 New
KBC Group
162
KBC Group
Belgium
$2.37M – – –
LSERS
163
Louisiana State Employees Retirement System
Louisiana
$2.36M +$2.55M +24,300 New
EAM
164
Erste Asset Management
Austria
$2.35M – – –
PI
165
Putnam Investments
Massachusetts
$2.33M -$121K -1,156 -5%
WG
166
Winton Group
United Kingdom
$2.21M +$122K +1,165 +5%
OAM
167
Optimal Asset Management
California
$2.21M +$671K +6,400 +39%
MLICM
168
Metropolitan Life Insurance Company (MetLife)
New York
$2.2M +$1.64M +15,640 +224%
ProShare Advisors
169
ProShare Advisors
Maryland
$2.14M +$618K +5,893 +37%
CIP
170
Chartwell Investment Partners
Pennsylvania
$2.13M -$228K -2,175 -9%
CAM
171
ClariVest Asset Management
California
$2.12M -$21K -200 -0.9%
PA
172
Profund Advisors
Maryland
$2.1M +$266K +2,540 +13%
SFI
173
Susquehanna Fundamental Investments
Pennsylvania
$2.08M -$41.5K -396 -2%
AAM
174
Advisors Asset Management
Colorado
$2.06M +$70K +668 +3%
BF
175
BOK Financial
Oklahoma
$1.97M +$139K +1,322 +7%
5 6
7
8 9

NBIX Hedge Fund Activity: Q1 2021 in Review

419 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2021, worth a combined $9.23B — up 7.4% from $8.6B a quarter earlier.

Buyers outnumbered sellers: 77 funds opened new NBIX positions and 60 closed out — a net gain of 17 holders — while 161 added to existing stakes and 127 trimmed.

The largest buyer was BlackRock, adding an estimated $419M. The largest seller was Capital International Investors, cutting an estimated $193M.

  • 419 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2021, up from 405 in Q4 2020.
  • Funds reported $9.23B of Neurocrine Biosciences stock for Q1 2021, up 7.4% quarter-over-quarter.
  • 77 funds opened new Neurocrine Biosciences positions in Q1 2021 and 60 closed out, a net change of +17 holders.
  • The largest Neurocrine Biosciences buyer in Q1 2021 was BlackRock, an estimated $419M added.
  • The largest Neurocrine Biosciences seller in Q1 2021 was Capital International Investors, an estimated $193M sold.

Based on aggregated 13F filings for Q1 2021.